InKemia joins Mind the Byte shareholders
The Catalan company also recently announced new scientific results and strategic agreements

InKemia IUCT Group, the biotechnology and high-technology SME holding company that is traded on the Alternative Stock Market (MAB), has acquired a 5% share in start-up Mind the Byte, located in the Barcelona Science Park and specializing in cloud-computing solutions for biotechnology and biomedical research.
InKemia IUCT Group will have a representative on the board of directors as a strategic partner of Mind the Byte, which just closed a €200,000 round of funding to accelerate the development and marketing of its SaaS platforms (Software as a Service) for drug discovery.
The transaction has also led the two companies to sign a collaboration agreement that will allow them to share customers, products and services, as well as permitting Mind the Byte to offer complete packages, from software or service design to product synthesis.
This injection of capital will give the start-up the chance to obtain the resources necessary to consolidate and internationalize its products and services. “Moreover, the collaboration contract with InKemia IUCT enriches our portfolio, complementing both experiences (computational and laboratory), and facilitates the entry into new markets, resulting from the territorial expansion that the group is experiencing," explained Alfons Nonell-Canals, CEO and founder of Mind the Byte.
President of InKemia IUCT, Josep Castells, said that "for InKemia, joining the Mind the Byte project is a great opportunity to enrich the group’s knowledge base in bioinformatics", strengthening the structure of services they can offer clients as well as their own potential to boost the efficacy and efficiency of internal R&D processes.
InKemia IUCT also recently announced positive new results in their research into Parkinson’s drugs, as well as extending the joint venture with Hungarian company Avidin Biotech to develop new drugs for diseases like breast, liver and lung cancer or inflammatory conditions.
Related news: